66 filings
Page 3 of 4
8-K
2ua vpp1dthlfd2s6oi
18 Mar 21
Applied Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results
7:22am
8-K
2kx2ojnmhur
17 Feb 21
Entry into a Material Definitive Agreement
5:05pm
8-K
xhvkg83 zt6
12 Nov 20
Applied Therapeutics Reports Third Quarter 2020 Financial Results
7:07am
8-K
hajwb
17 Aug 20
Other Events
8:25am
8-K
p0ui2x5ag
11 Aug 20
Applied Therapeutics Reports Second Quarter 2020 Financial Results
7:07am
8-K
amh0lpn4
5 Jun 20
Departure of Directors or Certain Officers
4:48pm
8-K
4fxy6gabm50p
26 May 20
Departure of Directors or Certain Officers
8:09am
8-K
p9ha6gpi
11 May 20
Applied Therapeutics Reports First Quarter 2020 Financial Results
7:07am
8-K
96l73ttm
21 Apr 20
Applied Therapeutics Announces Full Data and Scientific Presentations from the Pivotal Phase 2 ACTION-Galactosemia Trial
7:29am
8-K
tjg5m0d hcwwc
1 Apr 20
Departure of Directors or Certain Officers
5:11pm
8-K
5kieq jnvkdwm3i
13 Mar 20
Applied Therapeutics Reports Fourth Quarter and Year-end 2019 Financial Results
7:01am
8-K
zg3s33
14 Feb 20
Other Events
5:02pm
8-K
n5rere2sj ctpeblzpy
13 Nov 19
Applied Therapeutics Reports Third Quarter 2019 Financial Results
7:15am
8-K
ibdzbt2vw2apyvd6ne1
12 Nov 19
Applied Therapeutics, Inc. Announces Pricing of $20 Million Private Placement of Common Stock
9:24am
8-K
064er1r nq6awvzofn6n
4 Sep 19
Departure of Directors or Certain Officers
5:06pm
8-K
24p d1aiuzakb763n
4 Sep 19
Other Events
8:00am
8-K
r5o343dk8t9l4 1zk
12 Aug 19
Applied Therapeutics Reports Second Quarter 2019 Financial Results
7:16am
8-K
nctq7t8 aa8b814l
8 Aug 19
Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study
7:00am
8-K
kfa8w4sxhcn58
6 Aug 19
Regulation FD Disclosure
8:10am
8-K
30muv29ar jo23cns
24 Jun 19
Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 In Galactosemia
7:09am